Status:
UNKNOWN
Clinical Long Term Evaluation of Glutamine Supplement in MELAS Syndrome
Lead Sponsor:
Hospital Universitario 12 de Octubre
Conditions:
MELAS Syndrome
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to assesses the clinical efficacy of oral supplementation with glutamine over 3 years.
Detailed Description
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is a genetically heterogeneous disorder. The most common mutation is in the mtDNA gene MT-TL1 encoding the m...
Eligibility Criteria
Inclusion
- MELAS syndrome Clinically and genetically confirmed.
- Patients have already participated in GLN-9-MIT study
Exclusion
- subjects harboring a MELAS-related pathogenic mtDNA mutation no fulfilling the complete diagnostic criteria for the MELAS phenotype
Key Trial Info
Start Date :
July 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 24 2024
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT05255328
Start Date
July 1 2021
End Date
July 24 2024
Last Update
September 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041